Fungal Resistance in Dermatophyte Infection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Antifungal susceptibility testing (AFST).
- Who it may be relevant to
- Registry conditions: Dermatophyte Infection. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Species Identification and Antifungal Susceptibility Testing of Dermatophytes Isolated From Patients Attending Dermatology Outpatient Clinic at Kasr Alainy Hospitals
Overview
The aim of the study is to compare the efficiency of broth microdilution versus disk diffusion method for antifungal drug susceptibility testing of the most used drugs in dermatophytosis treatment.
Interventions
- Diagnostic test Antifungal susceptibility testing (AFST)
testing the fungal susceptibility to different drugs
Primary outcome measures
- Precent susceptibility to each drug [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Patients diagnosed clinically with dermatophytosis, any age group and any sex
Exclusion criteria
- Patients under either Local or systemic antifungal treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-only
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06729216 · Cutaneous Fungal resistance